Combination stacks
Ipamorelin and CJC-1295: The Common Research Stack
Two peptides, two receptors, one growth-hormone axis. The published rationale, the synergy numbers, and the trial that was never run.
Before the details
Ipamorelin cjc-1295 is the single most-searched growth-hormone peptide stack, and the reason it is paired is genuinely scientific — but the evidence for the pair is thinner than the popularity suggests. The two peptides hit growth hormone through two different receptors: ipamorelin works on the ghrelin receptor, CJC-1295 on the GHRH receptor. Pushing both doors at once can release more growth hormone than pushing either alone [8][13].
The honest catch is the one this whole page keeps returning to: the combination itself has never been tested as a finished product in a controlled human trial. The case for it is assembled from each peptide studied separately, plus studies of other peptides in the same two families combined [7][8][9]. The 2024 narrative review that orthopaedic physicians cite found the pair improved muscle tension in a mouse model of steroid-induced muscle loss — but explicitly noted the evidence is limited to animal studies [17]. So this page reads the rationale and the numbers, keeps the single-agent findings labeled as such, and is direct about the gap.
What is cjc 1295 ipamorelin
What is cjc 1295 ipamorelin: it is the pairing of two complementary growth-hormone-releasing peptides. CJC-1295 is a long-acting analog of growth-hormone-releasing hormone (GHRH) — it mimics the body's own GHRH signal and, in its DAC form, lasts for days. Ipamorelin is a short-acting, selective ghrelin-receptor (GHS-R1a) agonist that fires a single sharp growth-hormone pulse and clears in about two hours [2]. Combined, the idea is that CJC-1295 raises the baseline GHRH drive while ipamorelin adds discrete pulses on top — two mechanisms that are additive by design rather than redundant. CJC-1295's own human data show 2- to 10-fold growth-hormone increases for six-plus days after a single subcutaneous dose while preserving the natural pulsatile rhythm [13]. The combination is a research concept built on those separate pharmacologies; it is not an approved or trial-validated drug product.
Does cjc-1295 ipamorelin work
Does cjc-1295 ipamorelin work: for raising growth hormone in the short term, the underlying mechanism is sound and the class-level human data support synergy — but no controlled human outcome trial of this specific combination has demonstrated a wellness benefit. What exists is suggestive and indirect. Hexarelin plus GHRH produced true synergism in healthy men (p=0.001), exceeding the sum of each alone [8]. GHRP-2 plus GHRH over 30 days drove greater pulsatile growth-hormone output than either agent alone, with sustained IGF-1 [7]. A 2024 orthopaedic narrative review reported that CJC-1295 + ipamorelin improved maximal muscle tetanic tension in a glucocorticoid-induced muscle-loss mouse model — while stating the evidence is limited to animal studies [17]. A 2026 sports-medicine review of approved and unapproved peptides described ipamorelin as an investigational secretagogue with preclinical signals, emphasizing the absence of rigorous human trials and the potential for serious harm [18]. The growth-hormone pulse is real; the proven human outcome is not.
The two-receptor rationale
The pharmacology is the cleanest part of the story. Ipamorelin binds GHS-R1a (the ghrelin receptor) on pituitary somatotrophs, releasing growth hormone via a calcium-driven pulse without raising cortisol or prolactin [1]. CJC-1295 binds the GHRH receptor, a separate pathway that works through cAMP. Because the two receptors and their signaling cascades are distinct, their growth-hormone effects can stack rather than cancel. Continuous stimulation by a long-acting GHRH analog does not abolish the natural growth-hormone rhythm — pulsatility persists — which is the physiological argument for combining a steady GHRH analog with a pulsatile GHRP [13]. A 34-hour GHRP-6 infusion amplified the growth-hormone response to superimposed GHRH boluses, demonstrating the potentiation directly [9]. This is the mechanism the entire stack is built on.
Ipamorelin vs tesamorelin
Ipamorelin vs tesamorelin is a comparison across two different peptide classes, not two versions of the same thing. Tesamorelin is a stabilized GHRH analog — like CJC-1295, it works on the GHRH receptor — and unlike ipamorelin, it is an FDA-approved drug, approved specifically for reducing excess abdominal fat in HIV-associated lipodystrophy. Ipamorelin is a ghrelin-receptor agonist (a GHRP), is not approved for anything, and its only controlled human trial failed [3]. In a stack, tesamorelin would occupy the same GHRH-side role CJC-1295 plays; ipamorelin would supply the complementary ghrelin-receptor pulse. The key honest distinction: tesamorelin has an approved human indication and a real human evidence base, whereas ipamorelin's human record is one PK study and one failed trial [2][3]. They are not interchangeable, and pairing two GHRH analogs would be redundant rather than synergistic.
The evidence gap, stated plainly
The combination-protocol evidence gap is the single most important thing to carry away. The popular CJC-1295 + ipamorelin stack is supported by separate single-agent pharmacology and by class-level synergy studies of related peptides — not by any controlled trial of the combination for any outcome [13][17]. Marketing for anti-aging, fat loss, and muscle gain rests largely on mechanism and short animal studies, not on human outcome trials [11]. Neither peptide is FDA-approved; both are prohibited in sport; and the long-term safety of driving the growth-hormone axis harder with two agents is uncharacterized. The mechanism is real. The tested product is not.